Funding
Funding not disclosed
Founders
Product
Problem
Developing novel therapeutic candidates for unmet medical needs requires sophisticated molecular biology techniques and a robust platform for identifying and validating drug targets. The process of translating scientific discovery into viable treatments is often hampered by the complexity of biological systems and the need for precise molecular manipulation.
Solution
Anemoi Bio is a biotechnology company specializing in the discovery and development of novel therapeutic candidates. The company employs advanced molecular biology techniques to identify and validate drug targets, focusing on addressing significant unmet medical needs. Anemoi Bio's platform is designed to accelerate the preclinical development of innovative treatments across various disease areas. Their approach integrates cutting-edge research with a systematic methodology to advance promising molecular entities from discovery through to early-stage development.
Target Audience
Anemoi Bio targets pharmaceutical companies and academic research institutions seeking to advance novel therapeutic candidates through preclinical development.
Features
- Proprietary platform for target identification and validation utilizing advanced genomic and proteomic analysis.
- Expertise in molecular cloning, gene editing technologies (e.g., CRISPR-Cas9), and recombinant protein expression.
- Development of novel small molecules and biologics targeting specific disease pathways.
- In vitro and in vivo assay development for efficacy and safety profiling of therapeutic candidates.
- Preclinical study design and execution to support IND-enabling activities.